186 related articles for article (PubMed ID: 29944172)
1. A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
Cho M; Honda T; Ueshima C; Kataoka T; Otsuka A; Kabashima K
Acta Derm Venereol; 2018 Nov; 98(10):975-976. PubMed ID: 29944172
[No Abstract] [Full Text] [Related]
2. Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
Krase IZ; Cavanaugh K; Curiel-Lewandrowski C
JAMA Dermatol; 2016 Mar; 152(3):348-50. PubMed ID: 26536384
[No Abstract] [Full Text] [Related]
3. A case of severe pityriasis rubra pilaris with a dramatic response to apremilast.
Pellonnet L; Beltzung F; Franck F; Rouanet J; D'incan M
Eur J Dermatol; 2018 Feb; 28(1):128-129. PubMed ID: 29400288
[No Abstract] [Full Text] [Related]
4. Successful Treatment of Refractory Type 1 Pityriasis Rubra Pilaris With Apremilast.
Molina-Figuera E; González-Cantero Á; Martínez-Lorenzo E; Sánchez-Moya AI; García-Olmedo O; Gómez-Dorado B; Schoendorff-Ortega C
J Cutan Med Surg; 2018; 22(1):104-105. PubMed ID: 29309244
[No Abstract] [Full Text] [Related]
5. Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey.
Maloney NJ; Kim MM; Nguyen KA; Hisaw LD; Worswick S
Dermatol Ther; 2019 Sep; 32(5):e13060. PubMed ID: 31397958
[No Abstract] [Full Text] [Related]
6. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
7. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
[No Abstract] [Full Text] [Related]
8. Oral pityriasis rubra pilaris.
Martinez Calixto LE; Suresh L; Matsumura E; Aguirre A; Radfar L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 May; 101(5):604-7. PubMed ID: 16632271
[TBL] [Abstract][Full Text] [Related]
9. Successful use of etanercept in type I pityriasis rubra pilaris.
Seckin D; Tula E; Ergun T
Br J Dermatol; 2008 Mar; 158(3):642-4. PubMed ID: 18081896
[No Abstract] [Full Text] [Related]
10. Pityriasis rubra pilaris.
White KL
Dermatol Online J; 2003 Oct; 9(4):6. PubMed ID: 14594579
[TBL] [Abstract][Full Text] [Related]
11. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
Gómez M; Ruelas ME; Welsh O; Arcaute HD; Ocampo-Candiani J
J Drugs Dermatol; 2007 Mar; 6(3):337-9. PubMed ID: 17373198
[TBL] [Abstract][Full Text] [Related]
12. Chronic tearing induced by apremilast.
Norris MR; Bielory L
Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
[No Abstract] [Full Text] [Related]
13. Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists.
Vujic I; Richter L; Bartsch K; Monshi B; Rappersberger K
Eur J Dermatol; 2013; 23(6):895-6. PubMed ID: 24192269
[No Abstract] [Full Text] [Related]
14. Successful treatment of refractory Hailey-Hailey disease with apremilast.
Di Altobrando A; Sacchelli L; Patrizi A; Bardazzi F
Clin Exp Dermatol; 2020 Jul; 45(5):604-605. PubMed ID: 31930532
[No Abstract] [Full Text] [Related]
15. Pityriasis rubra pilaris, type 1.
Booth AV; Ma L
Dermatol Online J; 2005 Dec; 11(4):9. PubMed ID: 16403381
[TBL] [Abstract][Full Text] [Related]
16. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
17. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
18. The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation.
Inoue E; Arase N; Hanaoka Y; Tanemura A; Fujimoto M
Dermatol Ther; 2021 Jan; 34(1):e14714. PubMed ID: 33368948
[No Abstract] [Full Text] [Related]
19. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy.
Borok M; Lowe NJ
J Am Acad Dermatol; 1990 May; 22(5 Pt 1):792-5. PubMed ID: 2347965
[TBL] [Abstract][Full Text] [Related]
20. Pityriasis rubra pilaris successfully treated with infliximab.
Ruiz-Genao DP; Lopez-Estebaranz JL; Naz-Villalba E; Gamo-Villegas R; Calzado-Villarreal L; Pinedo-Moraleda F
Acta Derm Venereol; 2007; 87(6):552-3. PubMed ID: 17989902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
